August 27th, 2012
IABP Randomized Trial Delivers a Shock
holgerthiele131
The lead author of the IABP-SHOCK II trial discusses the practical implications of his study group’s findings.
August 27th, 2012
ESC: No Benefit of Intraaortic Balloon Counterpulsation in Cardiogenic Shock
Larry Husten, PHD
Despite a lack of evidence, circulatory support with intraaortic balloon counterpulation (IABP) has a class 1 recommendation in the guidelines and is often used in patients in cardiogenic shock following myocardial infarction for whom early revascularization is planned. That situation may change soon, as no benefit was found for the use of IABP in the […]
August 26th, 2012
Prasugrel vs. Clopidogrel in ACS: The TRILOGY Take
John Ryan, MD
TRILOGY author Matt Roe answers CardioExchange’s questions about his team’s study of clopidogrel vs. prasugrel in ACS.
August 26th, 2012
First Detailed Look At Why Aliskiren Failed To Gain ALTITUDE
Larry Husten, PHD
This once-promising renin inhibitor was no better than placebo when it came to the composite outcome, but showed worrisome trends, especially when it came to stroke.
August 26th, 2012
TRILOGY at ESC: No Advantage for Prasugrel Over Clopidogrel in Medical ACS Patients
Larry Husten, PHD
The newer antiplatelet agent prasugrel was no better than the old standby clopidogrel for treating patients with acute coronary syndrome (ACS) who are not undergoing revascularization. The results of the TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) trial were presented by Matt Roe at the European Society of […]
August 25th, 2012
New Universal Definition of MI Unveiled at ESC 2012
Larry Husten, PHD
The new definition specifies the troponin levels required to make a diagnosis of myocardial infarction in various situations.
August 24th, 2012
Is Bad News About Fibrates Getting Buried?
Harlan M. Krumholz, MD, SM
A meta-analysis about lipid-modifying therapies and risk for pancreatitis focuses on a benefit of statins but de-emphasizes potential harm from fibrates.
August 24th, 2012
Topol: The Clinical Trial World Is “Contrived”
Harlan M. Krumholz, MD, SM
Eric Topol says it’s time to “get rid of the randomized trial.” What do you say?
August 23rd, 2012
New DES Get COMFORTABLE with AMI
Richard A. Lange, MD, MBA and L. David Hillis, MD
The use of drug-eluting stents (DES) in patients with acute myocardial infarction (AMI) has recently generated concern. In two meta-analyses (De Luca et al and Kaleson et al) , the use of early-generation DES resulted in a lower risk of repeat revascularization compared with bare-metal stents (BMS) in patients with AMI, but the DES group had a 2-fold increased […]
August 22nd, 2012
NHLBI Announces 7000-Patient Trial to Test Inflammation Hypothesis
Larry Husten, PHD
The National Heart, Lung, and Blood Institute (NHLBI) has announced the launch of a large clinical trial testing the inflammation hypothesis. Paul Ridker is the principal investigator of the trial, which will be known as the Cardiovascular Inflammation Reduction Trial (CIRT). CIRT will enroll 7,000 patients who are stable following a heart attack but are at high risk for […]